The Department of Health expects to issue guidance on how to comply with the Prescription Drug Price Transparency Act by early summer 2021, which will include technical definitions and reporting requirements for the act. MDH will share information related to the act’s implementation and opportunities for public feedback on this page, through GovDelivery bulletins, and via State Register announcements. Stakeholders interested in receiving announcements on implementation of the act may subscribe to Prescription Drug Price Transparency updates.
For more information, contact NACDS’ Jill McCormack at 717-592-8977.